PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Translational Radiation Oncology"
DOI: 10.1016/j.ctro.2018.06.001
Abstract: Highlights • Summary of a protocol for a phase I study combining the ATR inhibitor and palliative radiotherapy.• Study design is discussed.• Study aims and objectives, brief eligibility criteria, DLT criteria and dose escalation is… read more here.
Keywords: phase study; atr inhibitor; study; radiation ... See more keywords
Abstract CT271: Translational analyses of ATR inhibitor M1774 in a Phase I study in patients with solid tumors (DDRiver Solid Tumors 301)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct271
Abstract: Background: Ataxia telangiectasia and Rad3-related (ATR) protein kinase plays a critical role in the DNA damage response. M1774, a potent, selective, orally administered ATR inhibitor with antitumor activity in preclinical models, was evaluated as monotherapy… read more here.
Keywords: m1774; atr inhibitor; inhibitor; solid tumors ... See more keywords
Abstract B21: The selective ATR inhibitor VX-970 enhances the therapeutic effects of standards of care in glioblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.dnarepair16-b21
Abstract: Glioblastoma (GBM) represents one of the most aggressive cancer types with the vast majority of patients succumbing to disease within the first five years. This dire prognosis reflects the limited efficacy of our frontline therapies… read more here.
Keywords: selective atr; atr inhibitor; glioblastoma; inhibitor 970 ... See more keywords
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.02404
Abstract: PURPOSE Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin. PATIENTS… read more here.
Keywords: response; monotherapy; atr inhibitor; carboplatin patients ... See more keywords
A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.tps3153
Abstract: TPS3153Background: Ataxia telangiectasia and Rad3-related (ATR) protein kinase plays a critical role in the DNA damage response by sensing and responding to DNA replication stress, and by inducing ... read more here.
Keywords: first human; study atr; atr inhibitor; inhibitor m1774 ... See more keywords
Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.999626
Abstract: ARID1A is frequently mutated in colorectal cancer (CRC) cells. Loss of ARID1A function compromises DNA damage repair and increases the reliance of tumor cells on ATR-dependent DNA repair pathways. Here, we investigated the effect of… read more here.
Keywords: arid1a deficient; vulnerability arid1a; atr inhibitor; deficient ... See more keywords